key: cord-0696230-iwl31m33
authors: Cerutti, Gabriele; Guo, Yicheng; Wang, Pengfei; Nair, Manoj S.; Wang, Maple; Huang, Yaoxing; Yu, Jian; Liu, Lihong; Katsamba, Phinikoula S.; Bahna, Fabiana; Reddem, Eswar R.; Kwong, Peter D.; Ho, David D.; Sheng, Zizhang; Shapiro, Lawrence
title: Neutralizing antibody 5-7 defines a distinct site of vulnerability in SARS-CoV-2 spike N-terminal domain
date: 2021-10-16
journal: Cell Rep
DOI: 10.1016/j.celrep.2021.109928
sha: aa50a4892367a4f488e26f637779d75f7a6e06d9
doc_id: 696230
cord_uid: iwl31m33

Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here we report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop into an exposed hydrophobic pocket between the two sheets of the NTD β-sandwich. Interestingly, this pocket has been previously identified as the binding site for hydrophobic molecules including heme metabolites, but we observe their presence to not substantially impede 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains a distinctive neutralization potency with variants of concern (VOC). Overall, we reveal a hydrophobic pocket in NTD proposed for immune evasion can actually be used by the immune system for recognition.

Antibodies that potently neutralize SARS-CoV-2 target mainly the receptor-binding domain or 24 the N-terminal domain (NTD). Over a dozen potently neutralizing NTD-directed antibodies have 25 been studied structurally, and all target a single antigenic supersite in NTD (site 1). Here we 26 report the cryo-EM structure of a potent NTD-directed neutralizing antibody 5-7, which 27 recognizes a site distinct from other potently neutralizing antibodies, inserting a binding loop 28 into an exposed hydrophobic pocket between the two sheets of the NTD -sandwich. 29

Interestingly, this pocket has been previously identified as the binding site for hydrophobic 30 molecules including heme metabolites, but we observe their presence to not substantially impede 31 5-7 recognition. Mirroring its distinctive binding, antibody 5-7 retains a distinctive neutralization 32 potency with variants of concern (VOC). Overall, we reveal a hydrophobic pocket in NTD 33

proposed for immune evasion can actually be used by the immune system for recognition. 34 The spike protein is comprised of two subunits: the S1 subunit comprising the N-terminal 69 domain (NTD), RBD and several other subdomains, and the S2 subunit that mediates virus-cell 70 J o u r n a l P r e -p r o o f complex with SARS-CoV-2 spike, present neutralization data with VOC, and analyze the 117 recognized epitope. We show that the 5-7 binding site represents a second site of neutralization 118 vulnerability in SARS-CoV-2 NTD remote from most VOC mutations, underscoring the 119 potential therapeutic value of antibody 5-7. 120 121

Antibody 5-7 targets a hydrophobic pocket in NTD 124

From a complex of SARS-CoV-2 spike -stabilized by 2P mutations (Wrapp et al., 125 2020b) -with the antigen-binding fragment (Fab) of antibody 5-7, we collected single particle 126 data on a Titan Krios microscope, yielding a cryo-EM reconstruction to an overall resolution of 127 3.5 Å for the global refinement and 3.8 Å for the local refinement of the 5-7:NTD interface 128 ( Figure 1A, Figures S1, S2 , S3 and S4, Table S1 ). The major 3D class was C3-symmetrical 129 with three Fabs per trimer. Recognition of NTD by 5-7 was dominated by the heavy chain, which 130 buried 1074.2 Å 2 surface area, with a smaller 146.2 Å 2 contribution by the light chain. The 24 131 amino acid CDR H3 formed the dominant interaction with NTD, with additional contributions 132 from CDRs H1, H2, L1 and L3 ( Figure 1B; Figure S4A ). CDR H3 formed hydrophobic and 133 hydrogen bond contacts with NTD, in particular through residues near the tip of the CDR H3 134 loop, W1000f, S100h, L100i and K100j, which are within a short helix. Further toward the base 135 of CDR H3, two hydrogen bonds are formed with NTD and additional hydrophobic contacts are 136 formed, particularly with the side chain of CDR H3 Y100e. CDR H1 and H2 contributed to NTD 137 recognition mainly through hydrogen bonds involving N52 and S56 and hydrophobic contacts 138 involving Y33 and V50. Light chain interacted with NTD residues Q173 and P174 through 139 hydrogen bond and hydrophobic interactions, respectively ( Figure S4A) . 140 J o u r n a l P r e -p r o o f Antibody 5-7 targets a site distinct from the NTD supersite 142

Since other neutralizing antibodies targeting NTD recognize the site 1 antigenic supersite, 143

we compared the recognition of NTD by 5-7 and other neutralizing antibodies, most of which are 144 supersite antibodies. We produced a structural superposition of all NTD-directed antibodies 145 deposited in the PDB, superposed on NTD C atoms, in the context of SARS-CoV-2 spike 146 trimer (Figure 2A) . All neutralizing antibodies target the NTD supersite except for 5-7 and 147 P008_056; these two antibodies bind to different regions on the "side" of NTD. The single non-148 neutralizing antibody DH1052 binds to another region at the "bottom" of NTD. 149

Overall, the 5-7 recognition site and NTD supersite (as defined by (Cerutti et al., 2021a) 150 are distinct, with a small area of overlap. This can be seen in the ribbon diagram in Figure 2B To assess the potential breadth of 5-7, we compared the sequence entropy of its epitope 206 among SARS-CoV-2 sequences in the GISAID database to the sequence entropy of the supersite 207 targeted by neutralizing antibodies, and the rest of the NTD surface ( Figure 4B ). The sequence 208 entropy of the 5-7 epitope is about an order of magnitude lower than that of the supersite. Not 209 J o u r n a l P r e -p r o o f surprisingly, the W152 and R190 showed the highest entropy within the 5-7 interface, the other 210 residues are highly conserved. Overall, this shows that the 5-7 epitope has low variability, and 211 suggests that 5-7 can successfully target numerous circulating SARS-CoV-2 variants. 212 213 Discussion 214

The structure of 5-7 in complex with SARS-CoV-2 spike shows that potent neutralization 215 can be achieved by antibodies that target NTD outside of the site 1 supersite. In vitro 216 experiments suggest that supersite-directed antibodies neutralize not by blocking recognition of 217 the ACE2 receptor, but by inhibiting conformational changes required for fusion (Suryadevara et 218 al., 2021) . It is possible that 5-7, which binds at a site near to but distinct from the supersite and 219 also fails to inhibit interaction with ACE2 ( The pseudovirus neutralization showed that the potency of 5-7 does not decrease much (~4 fold) 242 with the addition of biliverdin. However, the potency of antibodies 5-24 and 4-8 are significantly 243 decreased by biliverdin (Figure S7A) , which is consistent with a previous study on other NTD-244 directed antibodies including an antibody P008_056 that recognize an epitope that overlaps 245 significantly with 5-7 (Rosa et al., 2021). The different impacts of biliverdin on these NTD-246 directed antibodies imply that 5-7 may neutralize SARS-CoV-2 with a mechanism different from 247 many other NTD-directed neutralizing antibodies. Our structural analysis further revealed that 248 antibody 5-7 competes with biliverdin differently from P008_056. Antibody 5-7 inserts its CDR 249 H3 directly to the binding pocket of biliverdin for competition, whereas P008_056 competes 250 with biliverdin by binding to the N4 loop to alter conformation of the biliverdin binding pocket 251 ( Figure S7B ). This hydrophobic pocket may play a role in SARS-CoV-2 biology, such as 252 interacting with a target protein ligand, but if so, this remains unknown. The binding of 253 biliverdin and bilirubin has been proposed as a means of viral evasion (Rosa et al., 2021) , though 254 we find here the immune system is able to generate an antibody that turns this binding pocket 255 into a site of vulnerability for antibody neutralization. 256

Among the more attractive properties of antibody 5-7 is the partial tolerance of its 257 neutralization to VOC mutations. We have shown here that this tolerance arises largely due to its 258 novel binding orientation, which leads to a lack of overlap of 5-7 with VOC mutations. Overall, 259

we have shown 5-7 to target a conserved epitope on NTD, increasing the number of known 260 neutralizing epitopes and enabling therapeutic strategies such as cocktail combinations or multi-261 specifics that target both NTD and RBD. 262 263

The cryo-EM reconstruction reported in this paper was sub-optimal in the constant region 265 of the Fab, probably due to flexibility with respect to the Fv region; deposited coordinates do not 266 include modeling of the CH1 and CL1 domains. Because of intrinsic flexibility of certain regions 267 of spike, the EM map did not allow modelling of the following regions: N2 and N5 loops of 268 NTD, S1/S2 cleavage site, the switch region and the C-terminus (residues >1145). 

Protein samples expression and purification 397 SARS-CoV-2 S2P spike was produced as described in (Wrapp et al., 2020b) Chimera (Pettersen et al., 2004) and Chimera X (Pettersen et al., 2021) . A summary of the cryo-459 EM data collection, reconstruction and refinement statistics is shown in Table S1 . were cultured overnight at 37 °C with 5% CO 2 , and VSV-G pseudo-typed ΔG-luciferase (G*ΔG-485 luciferase, Kerafast) was used to infect the cells in DMEM at a MOI of 3 for 2 hours before 486 washing the cells with 1X DPBS three times. The next day, the transfection supernatant was 487 harvested and clarified by centrifugation at 300 g for 10 min. Each viral stock was then 488 incubated with 20% I1 hybridoma (anti-VSV-G, ATCC: CRL-2700) supernatant for 1 hour at 37 489 °C to neutralize contaminating VSV-G pseudo-typed ΔG-luciferase virus before measuring titers 490 and making aliquots to be stored at -80 °C. 491 Neutralization assays were performed by incubating pseudoviruses with serial dilutions 492 of mAbs or heat-inactivated plasma or sera, and scored by the reduction in luciferase gene 493 expression as previously described (Wang et al., 2021c Binding experiments for each of the three Fabs binding to NTD were performed in a 520 ligand-free buffer that consisted of HBS-T pH 7.4 (10 mM HEPES pH 7.4, 150 mM NaCl, 521 0.05% (v/v) Tween-20), and in buffers each supplemented with ligands that have been reported 522 to bind to the NTD hydrophobic pocket such as 1) 0.2 μM biliverdin, 0.5% (v/v) DMSO, 2) 10 523 μM bilirubin, 1% (v/v) DMSO and 3) 0.01% (v/v) Polysorbate-80 (P-80). Fabs 5-7 and 5-24 524 were tested using a three-fold dilution series ranging from 1.1-270 nM, and 4-8 was analyzed at 525 concentrations ranging 1.1-90 nM, using also a three-fold dilution series. Each Fab was tested in 526 order of increasing protein concentration, in duplicate. The association and dissociation rates 527 were each monitored for 120 s and 600 s respectively, at 50 μL/min. The NTD surface was 528 regenerated using two-consecutive 10 s pulse of 15 mM H 3 PO 4 at a flow rate of 100 μL/min, 529 followed by a 60 s buffer wash at the same flow rate. Blank buffer cycles were performed by 530 injecting running buffer instead of Fab to remove systematic noise from the binding signal. The 531 data was processed and fit to 1:1 interaction model using the Scrubber 2.0 (BioLogic Software). 532 533 Antibody gene assignments and genetic analyses 534

The 13 NTD-directed SARS-COV-2 neutralizing and 1 non-neutralizing antibodies were 535 collected from six publications. We annotated these antibodies using IgBLAST-1. 16 The residues of 5-7 paratope were obtained by PDBePISA (Krissinel and Henrick, 2007) , 543 with the default parameters. Per residue sequence entropy was download from the next strain 544 database (Hadfield et al., 2018) , which enabled by data from GISAID (https://www.gisaid.org/). 545

The p value among different paratope groups were calculated by Kolmogorov-Smirnov test in R, 546 with the significant level set as p < 0.05. The geometric mean and 95% CI of per residue 547 sequence entropy were calculated and plotted by GraphPad Prism version 9. The visualization of 548 

Recent developments in the PHENIX 562 software for automated crystallographic structure determination

Structure of a germline-like human antibody defines a 566 neutralizing epitope on the SARS-CoV-2 spike NTD. bioRxiv

A Novel SARS-CoV-2 Variant of Concern, B.1.526

Structural analysis of full-length SARS-CoV-572 2 spike protein from an advanced vaccine candidate

EMRinger: side chain-directed model and map validation for 3D cryo-electron microscopy

SARS-CoV-2 neutralizing antibody 578 structures inform therapeutic strategies

Structures of Human

Antibodies Bound to SARS-CoV-2 Spike Reveal Common Epitopes and Recurrent Features of 582 Antibodies

Receptor binding and priming of the spike protein of SARS-CoV-2 for 585 membrane fusion

Positive-unlabeled convolutional neural networks for particle picking in cryo-electron 588 micrographs

IMGT/V-QUEST: the highly customized and 590 integrated system for IG and TR standardized V-J and V-D-J sequence analysis

Potent neutralizing antibodies from 594 COVID-19 patients define multiple targets of vulnerability

The coronavirus 596 pandemic in five powerful charts

Potent neutralizing antibodies against SARS-CoV-2 identified by high-throughput single-599 cell sequencing of convalescent patients' B cells

Potent SARS-CoV-2 neutralizing antibodies directed against spike N-602 terminal domain target a single supersite

Structural Basis for Accommodation of Emerging B.1.351 and B.1.1.7 Variants 605 by Two Potent SARS-CoV-2 Neutralizing Antibodies

Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin 608 converting enzyme 2 receptor

WHO Declares COVID-19 a Pandemic

MOLPROBITY: structure 615 validation and all-atom contact analysis for nucleic acids and their complexes

An interactive web-based dashboard to track COVID-19 618 in real time

SAbPred: a structure-based antibody prediction server. 621

Coot: model-building tools for molecular graphics

Rep: A Database of 625

Curated Antibody Repertoires for Exploring Antibody Diversity and Predicting Antibody 626 Prevalence

Nextstrain: real-time tracking of pathogen evolution

Human neutralizing antibodies elicited by SARS-CoV-2 infection

Inference of macromolecular assemblies from crystalline 634 state

The functions of SARS-CoV-2 neutralizing and infection-637 enhancing antibodies in vitro and in mice and nonhuman primates. bioRxiv

Potent neutralizing antibodies against multiple epitopes on SARS-CoV-2 spike. 641

Neutralizing Antibodies Isolated by a site-directed Screening have Potent Protection on SARS-644

CoV-2 Infection. bioRxiv

SARS-CoV-2 immune evasion by variant 647 B.1.427/B.1.429. bioRxiv

N-terminal domain antigenic mapping reveals a site of 650 vulnerability for SARS-CoV-2

Genomic characterisation of an emergent SARS-CoV-2 lineage in Manaus: 654 preliminary findings

UCSF Chimera--a visualization system for exploratory research and analysis

UCSF ChimeraX: Structure visualization for researchers, educators, and 660 developers

Structural and functional analysis of a potent sarbecovirus 663 neutralizing antibody. bioRxiv

cryoSPARC: algorithms for 665 rapid unsupervised cryo-EM structure determination

Modular basis for potent SARS-CoV-2 neutralization by a prevalent 668 VH1-2-derived antibody class. bioRxiv

Convergent antibody responses to SARS-CoV-2 in 671 convalescent individuals

Isolation of potent SARS-CoV-2 neutralizing antibodies and protection 674 from disease in a small animal model

SARS-CoV-2 can recruit a haem metabolite to evade antibody 677 immunity

RELION: implementation of a Bayesian approach to cryo-EM structure 679 determination

Characterization of neutralizing antibodies 682 from a SARS-CoV-2 infected individual. bioRxiv

ABCB10 exports mitochondrial biliverdin, 685 driving metabolic maladaptation in obesity

Automated molecular microscopy: the new Leginon system

Neutralizing and protective human 691 monoclonal antibodies recognizing the N-terminal domain of the SARS-CoV-2 spike protein

Emergence of a new SARS-CoV-2 variant in the 694 UK

Emergence and rapid spread of a new severe acute 697 respiratory syndrome-related coronavirus 2 (SARS-CoV-2) lineage with multiple spike mutations 698 in South Africa. medRxiv

Prevalent, protective, and convergent IgG 701 recognition of SARS-CoV-2 non-RBD spike epitopes

Antigenicity of the SARS-CoV-2 Spike Glycoprotein

A human monoclonal antibody 706 blocking SARS-CoV-2 infection

Structure-based development of human antibody cocktails against SARS-CoV-2

Increased resistance of SARS-CoV-2 variant P.1 to antibody 712 neutralization

Antibody resistance of SARS-CoV-2 variants B

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2

Structural Basis for Potent 720 Neutralization of Betacoronaviruses by Single-Domain Camelid Antibodies

Cryo-EM structure of the 2019-nCoV spike in the prefusion 724 conformation

A natural mutation between SARS-CoV-2 and SARS-CoV determines 727 neutralization by a cross-reactive antibody. bioRxiv

A 729 noncompeting pair of human neutralizing antibodies block COVID-19 virus binding to its 730 receptor ACE2

Neutralization of variant under investigation B.1.617 733 with sera of BBV152 vaccinees. bioRxiv

Structural basis for the recognition 735 of SARS-CoV-2 by full-length human ACE2

IgBLAST: an immunoglobulin variable 737 domain sequence analysis tool

Structural basis of a shared antibody response to SARS-CoV-2

Isolation of a human monoclonal antibody specific for the receptor binding domain of SARS-742

CoV-2 using a competitive phage biopanning strategy

Emergence of a novel SARS-CoV-2 strain in Southern California, USA. medRxiv

Cryo-EM Structures of SARS-CoV-2 Spike 748 without and with ACE2 Reveal a pH-Dependent Switch to Mediate Endosomal Positioning of 749 Receptor-Binding Domains

A Bayesian approach to beam-induced 751 motion correction in cryo-EM single-particle analysis

Rapid isolation and profiling of a diverse panel of 754 human monoclonal antibodies targeting the SARS-CoV-2 spike protein